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ABSTRACT
Cancer is one of the leading causes of death in the world with over 10 million people
dying of the disease every year. Inorganic complexes supported by platinum metal centers are
often used in cancer treatment. However, these complexes lack selectivity for tumor cells. As
such, other alternatives to platinum have been explored. Ruthenium (Ru) complexes are one of
the most promising candidates due to their ability to be used as photosensitizing drugs in
photodynamic therapy.
Herein, we report the design, synthesis, and characterization of two novel rutheniumbased complexes. One compound is a Ru(II) homoleptic complex, while the other is a
mononuclear Ru(II) complex that features an open coordination site. To probe the structural and
electronic properties of these complexes, we used nuclear magnetic resonance spectroscopy, Xray crystallography, UV-visible spectroscopy, and cyclic voltammetry. Future work for this
project involves measuring whether our complexes can generate singlet-oxygen in vitro upon
irradiation with light.
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CHAPTER I
AN INTRODUCTION TO PHOTODYNAMIC THERAPY, RUTHENIUM COMPLEXES,
THEIR APPLICATION AS PHOTOSENSITIZERS, AND EXPERIMENTAL DESIGN
Inorganic Complexes Indicated for Cancer
According to the CDC, cancer is one of the leading causes of death in the United States,
second only to heart disease. In 2020 alone, nearly 600,000 deaths were attributed to cancer.1,2
Cancer, which is characterized by unregulated cell growth that can metastasize to other parts of
the body, has been the subject of much research. Past work in this field has focused on
understanding the biochemical and genetic causes of cancer, how the disease manifests
clinically, and developing new therapeutics to treat it. Current cancer treatment protocols involve
the use of chemotherapeutics, surgical removal of tumors, and the application of radiation,
among other treatment types.3 Despite the diversity of treatment options, there is an increasing
focus to develop more treatments generally, and more novel chemotherapy drugs specifically. In
2020 for instance, nearly half of all the drugs approved by the FDA were indicated for cancer.4
The need for novel chemotherapies is a consequence of growing drug resistance among many
different types of cancer.5,6 As a result of increasing drug resistance, there is a medical need to
develop new anticancer drugs. One growing area of interest is to explore inorganic complexes as
novel, small-molecule chemotherapeutics.7
An often-overlooked application of transition metal complexes is their use as medicinal
agents. Though inorganic complexes have been widely explored for catalysis, small-molecule
1

2
activation, and active-site modeling, there is less robust literature supporting their use as drugs
compared to their organic counterparts. The lack of interest in considering coordination
complexes during the drug discovery process is likely due to the belief that metal-based
compounds are inherently dangerous and toxic.7 However, there are examples of metallodrugs
that have both diagnostic and therapeutic applications.8 For instance, one of the most common
metals used in medicine is platinum (Pt). Inorganic compounds supported by Pt are ubiquitous in
current cancer treatments. Indeed, about 50% of all cancer treatment regiments incorporate Ptbased anticancer drugs.9 This statistic demonstrates the potential for inorganic compounds in
medicine.
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Figure 1. Platinum-based anticancer drugs. Cisplatin, carboplatin, and oxaliplatin are the three
FDA approved medications which are supported by a Pt metal center. The Pt is in the +2
oxidation state and in a square planar geometry for all three compounds.
Platinum-based Chemotherapy Drugs
Thus far, three Pt-based anticancer drugs have been approved by the FDA for clinical
use: cisplatin, carboplatin, and oxaliplatin (Figure 1).10 Of these, cisplatin is one of the most wellknown, widely studied, and used coordination compounds in medicine. Cisplatin, or cis[Pt(NH3)2Cl2], is a square-planar coordination complex where two ammine and two chloro
ligands are oriented cis around a Pt(II) center. Clinically, cisplatin has been used to treat different
types of cancer including bladder cancer, ovarian cancer, and testicular cancer.11–14 However,
cisplatin has several serious side effects. The drug has been shown to affect bone marrow, lead to
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hair loss, damage the mucous membranes of the gastrointestinal tract, and it is particularly toxic
to the liver and kidneys.15
Medicinal applications for Pt metallodrugs are related to how they exert their anticancer
effect in the body. It is well understood that the main target for Pt-based anticancer drugs is
nuclear DNA. These compounds share a similar mechanism of action through the dissociation of
labile ligand(s). The resulting open coordination site allows for Pt to complex to DNA. All three
Pt compounds feature a square-planar geometry and the inclusion of leaving group ligands.16 The
first step is for the drug to be taken up by the cell. In the case of cisplatin, this is believed to be
facilitated by copper transporters.16,17 Next, aquation/activation takes place whereby a labile
chloro ligand is replaced by a water molecule to form cis-[Pt(NH3)2Cl(H2O)]+.16,18 From there,
aquated cisplatin can enter the nucleus. Then, the aqua ligand dissociates and the drug binds to
the purine bases of DNA: guanine and adenosine.16,18 Following substitution of the second chloro
ligand, the drug binds to another guanine base which causes DNA cross-linking. This prevents
DNA transcription and translation which leads to cell death.16,18
Limitation of Platinum-based Chemotherapies
Given the cytotoxic properties of the aforementioned Pt compounds, their use as cancer
treatments is a significant achievement in the field of medicinal inorganic chemistry. However,
the potential for Pt compounds to be used in chemotherapy is curbed due to many cancers
developing resistance to these types of drugs.5 Thus, some Pt chemotherapeutics like oxaliplatin
are often given in combination with other anticancer drugs, like fluorouracil.19 To combat
resistance to Pt chemotherapies and generate alternatives with milder side effect profiles,
chemists have worked to expand the scope of potential metallodrug candidates to other elements
in the d-block.
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Expanding the Scope of Inorganic Anticancer Compounds
One of the most promising alternatives to Pt in medicinal inorganic chemistry is
ruthenium (Ru). Metal complexes supported by Ru offer a few advantages to Pt. Two of the most
important considerations are cost and toxicity. Ru is significantly less expensive than Pt. As
such, metallodrugs which incorporate Ru centers should theoretically be more cost-effective than
their Pt counterparts. In addition, as mentioned by Bergamo and Sava, Ru-based complexes are
generally less toxic than Pt which can reduce the potential for chemotherapy-related side
effects.20 Given that Ru is lower cost and less toxic relative to Pt, it is a metal worth pursuing as a
Pt alternative in metal-based chemotherapy drugs.
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Figure 2. Examples of ruthenium complexes which have advanced to clinical trials. NAMI-A,
KP1091, and KP1339 are all examples of metal complexes supported by Ru(III) centers. These
complexes have been investigated for their anticancer properties. However, these three drug
candidates have not made it to market due to undesirable properties including side effects.
Ruthenium-based Anticancer Compounds
Several Ru complexes have undergone or are currently being evaluated in clinical trials.
These compounds are shown in Figure 2. NAMI-A initially failed to move beyond phase II
clinical trials due to side effects.21–23 However, it has been further evaluated in combination
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treatments.

23,24

Another compound, KP1019, failed to advance through clinical trials because it

was not very water soluble.23,25,26 The poor solubility of KP1019 was improved by generating an
analogue, KP1339.23,27Additionally, it is worth noting that NAMI-A, KP1019, and KP1339 are
all Ru(III) complexes. It is believed that these complexes act as prodrugs and are reduced from
Ru(III) to Ru(II) in cellular environments.25,28 Therefore, the active form of NAMI-A, KP1019,
and KP1339 is when the Ru center is in the +2 oxidation state.
Unlike Pt-based chemotherapeutics which are known to target DNA, the mechanism of
action of Ru complexes in tumor suppression is less well understood. As outlined by Lin and
colleagues, it is believed that Ru complexes exhibit their cytotoxic effect through multiple
mechanisms of action (Figure 3).23 It has been demonstrated that some Ru-based metallodrugs
may kills cells by targeting DNA and blocking the cell cycle during S-phase.23,29–31 Other reports
suggest that Ru complexes target organelles. For instance, some work has found that Ru
complexes may target mitochondria.23,32–34 In addition, other findings suggest that the
endoplasmic reticulum is a target of some Ru complexes.23,35 The aforementioned targets for Ru
compounds are not an exhaustive list. Rather, it describes a few notable examples which have
been reported in the literature. The multiple cellular targets of Ru complexes may allow them to
be less susceptible to drug resistance compared to Pt-based chemotherapies since Pt drugs
primarily target DNA.
While the preliminary results of Ru compounds as chemotherapy drugs candidates are
promising, they are not ideal since they do not selectively target cancer cells.36 As mentioned
before, one of the major hurdles in developing more organometallic chemotherapy drugs is the
issue of selectivity. Ideally, a drug should be selective for its target to minimize potential side
effects. In other words, a chemotherapy drug should be selective for cancerous cells while not
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targeting healthy cells. For example, cisplatin is cytotoxic to cancer cells because it cross-links
DNA. However, cisplatin lacks selectivity for cancer cells, and it is also cytotoxic to many noncancerous cell types.15
Ru

Membrane Damage

Endoplasmic
Reticulum
Mitochondria
Endoplasmic
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Figure 3. Cellular targets of ruthenium complexes. Ru complexes are known to target a variety of
cellular structures and organelles. Some Ru-based drug candidates are cytotoxic by interacting
with DNA which can lead to DNA damage and eventual cell death. Other Ru complexes target
the endoplasmic reticulum or mitochondria. In addition, some Ru complexes can target proteins
or the cellular membrane, which may lead to further damage. Lastly, a few Ru complexes can
interact with light and potentially be used in PDT (photodynamic therapy). This figure was
adapted from Lin and colleagues.23
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Though much work is being done to address the selectivity of traditional organometallic
drugs used in cancer treatment, there is growing interest in a different treatment modality where
the cytotoxicity of a metallodrug can be modulated both spatially and temporally through the
application of light. To this end, metal complexes supported by Ru are being investigated due to
their desirable chemical and photophysical properties. This approach has the potential to be as
efficacious as Pt-based anticancer drugs, while reducing the severity of side effects by employing
a unique mechanism of action.

Tumor

Tumor reduction or death
via generation of ROS

= Photosensitizer

Figure 4. Photodynamic therapy applied to tumor treatment. This diagram shows how PDT can
be used to treat a tumor. A photosensitizer (PS) is first given which can accumulate in a tumor
and surrounding tissue. Next, light is applied to the area of the tumor. The PS reacts with light to
generate reactive oxygen species (ROS). The ROS that are produced result in oxidative damage
and can lead to cell death, thereby killing the cancerous cells that make up the tumor. This figure
was adapted from Rui and colleagues.37
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Photodynamic Therapy as an Alternative Approach
In an effort to create a metal antitumor drug with enhanced selectivity for cancerous cells,
researchers have focused on developing a new class of drugs. PDT is a type of treatment most
often used in cancer therapies. PDT uses light and a molecule that can act as a photosensitizer
(PS).38 As outlined by Abrahamse and colleagues, PDT relies on the “damage or destruction of
living tissue by visible light in the presence of a photosensitizer and oxygen,” which is referred
to as the photodynamic effect.7,39 Thus, the cytotoxicity of a PS molecule can be “turned on” in
the presence of light and “turned off” or greatly reduced without the application of light (Figure
4). In doing so, the cytotoxic drug is mostly localized in the area exposed to light, as opposed to
the systemic cytotoxicity of traditional treatments.
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Figure 5. Examples of photosensitizers for cancer treatment. The structures of two PS, Photofrin
and TLD1433, are shown. Photofrin is one of the most used PS for PDT. The structure of
Photofrin was adapted and modifed from Josefsen and Boyle.40
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Clinical Uses of PDT
Clinically, PDT has been applied to treat a number of different types of cancer. One of
the first PS that was granted FDA approval is Photofrin (Figure 5). This drug is used in PDT for
the treatment of esophageal cancer and early non-small cell lung cancer.41 In recent years, new
photosensitizers have been developed which has expanded the scope of indications that can be
treated with PDT to include basal cell carcinoma, squamous cell carcinoma, and bladder cancer,
just to name a few.42,43 The three compounds that have been approved by the FDA for PDT in
cancer are based on porphyrin and porphyrin derivatives. One limitation of these compounds is
that they are excited by shorter wavelengths of light near the UV region. More structurally
diverse compounds based on Ru(II) have been investigated to shift the wavelength of light
needed to excite these PS to the visible or near-infrared region.7
Type I and Type II Mechanisms
As mentioned previously, PDT consists of three elements: a PS, light (which is of a
specific wavelength), and oxygen (O2).44,45 This point is important to emphasize because it relates
to how a PS is able to produce ROS, which is termed the photodynamic effect, as well as the
underlying photophysical and chemical mechanisms that govern its efficacy. Based on the
photodynamic effect, photoreactions for PDT can be classified as either following a type I or
type II mechanism. The distinction between these two types of mechanisms is based on what
type of ROS is produced.
PDT begins with the administration of a PS that is distributed to the tissue of interest.
Next, light is applied to the tissue and is absorbed by the PS, thereby initiating the photodynamic
effect. When the PS absorbs energy from a specific wavelength of light, one of its electrons is
promoted from its singlet ground state (1PS) to the singlet excited state (1PS*), as illustrated in the

Jabłonski diagram (Figure 6).

7,46,47
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From there, the system can reach a more stable electronic state

through intersystem crossing to the triplet excited state (3PS*) which requires the electron to
undergo spin conversion (Figure 6).7,48 The type of molecule to which 3PS* transfers energy to
determines whether the photodynamic effect follows a type I or type II mechanism.47 Regardless
of the type of mechanism, the photodynamic effect produces ROS such as singlet oxygen (1O2),
hydroxyl radical (HO•), or hydrogen peroxide (H2O2) which result in oxidative damage, thereby
killing the cell.44 As reported by Rocha, the quantum yield of 3PS* is an important factor in
determining the production of 1O2.49 Thus, an ideal photophysical property for a PS is that it has a
high quantum yield since it is related to the generation of 1O2 and other ROS.7
ROS
O2

Energy (eV)

1PS*

3PS*

1O
2

(O2−•, HO•, H2O2)

Type I Mechanism
(electron transfer)

Cell Death
1Σ
g

3Δ
g

1O
2

Type II Mechanism
(energy transfer)

3Σ
g

3O
2
1PS

Figure 6. Jabłonski diagram depicting the photodynamic effect. The Jabłonski diagram illustrates
how a PS absorbs energy from light and is promoted from 1PS to 1PS*. The PS then undergoes
intersystem crossing to reach 3PS*. The molecule to which 3PS* transfers energy to determines
whether the mechanism is type I or type II. Fluorescence and phosphorescence labels have been
omitted for clarity. The diagram is an adapted version from the works of Monro and Correia.7,45
If the photodynamic effect follows a type I mechanism, photoinduced electron transfer
occurs which produces radicals. If these radicals are in the presence of O2, they can generate
ROS like O2−•, HO•, and H2O2.7,45,49 In a type II mechanism, 3PS* transfers energy to O2, which is
in the triplet ground state. This energy transfer produces highly reactive 1O2, leading to oxidative
damage.7,45,49 One similarity between the pathways is that they both require O2 to produce ROS.
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It has been reported that of these two pathways, the type II mechanism occurs more
frequently.45,49 Though both type I and type II are expected to occur at the same time, they are
influenced by O2 concentration and the type of PS that is used.45,47,48,48
The benefit of PDT is that ROS are short-lived so much of the oxidative damage that
leads to cell death occurs in a limited area. This is one of the ways PDT differs from traditional
chemotherapies because the cytotoxic agent is restricted spatially to the area where light is
applied. In addition, PDT tends to cost less and leads to less tissue scarring compared to other
treatments.50,51 However, PDT has some drawbacks that has limited its clinical scope to certain
types of cancer. For example, PDT is not an efficient methods of treating cancers that have
spread to other tissues.45,50 Further, the ability of the photodynamic effect to generate oxidative
damage through ROS is limited because light cannot penetrate tissue very well.45,50,52 Therefore,
PDT is generally reserved for tumors that are located superficially on tissues.
Ruthenium Complexes Explored for PDT
Though much of the work on PS has been with organic molecules like porphyrin or
porphyrin derivatives, some researchers have focused on expanding the structural diversity of
these compounds to shift their absorbance from the near UV into the visible to near-infrared
regions. In recent years, effort has been made to synthesize PS for use in PDT that are supported
by transition metals. Complexes supported by d-block transition metals offer several features that
make them attractive PS candidates. Altering the oxidation state, changing the geometry around
the metal center, water solubility, and ligand tunability are just some parameters that can be
modified to enhance chemical and photophysical properties of a PS supported by a metal.7,53–55
One of the metals that has perhaps received the most attention for this endeavor is Ru.
Ru compounds have gained attention because they can potentially supplant traditional Pt-
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based chemotherapies for the treatment of certain types of cancer. For instance, Ru complexes
are expected to be just as efficacious as Pt anticancers, but with less toxicity and a higher degree
of selectivity, thereby reducing possible side effects.23,56–58 In addition, the cytotoxicity of
different Ru compounds is expected to have multiple mechanisms of action as shown in Figure 3.
Lastly, there is more robust literature examining how Ru complexes can function as PS
compared to Pt.7,23
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Scheme 1. Examples of ruthenium(II) complexes that function as photosensitizers. The
compound [Ru(bpy)3]2+ is one of the most well know and characterized Ru(II) PS. This
compound has led to the rise of other PS like [Ru(bpy)2(dpzz)]2+ and [Ru(bpy)2(6,6’-dmb]2+.
TLD-1433 is a Ru(II) complex which is currently being explored in clincal trials as a potential
cancer treatment. The following figure is adapted from the work of Monro and colleagues.7
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Ru is an attractive metal to support complexes that can function as a PS due to its
intrinsic chemical and photophysical properties. As described by Monro and colleagues, the
literature on Ru(II) PS systems is well established.7 Thus, a metal complex containing a Ru(II)
center is worth pursuing due to the precedent of it potentially functioning as a PS. Further,
Aksakal and coworkers note that the work on Ru(II) complexes with photosensitizing properties
has primarily focused on systems supported by polypyridyl ligands.33,59–61 Polypyridyl ligands are
N-heterocycles with conjugated π electrons. The electronic structure of this ligand system is
important for how Ru(II) complexes interact with light. As Aksakal and coworkers describe,
Ru(II) polypyridyl-based complexes are of interest because they have “long emission state
lifetimes from the triplet metal-to-ligand charge transfer state (MLCT)” that are quenched by 3O2
(triplet oxygen) which result in a high 1O2 quantum yield.33,59,61,62 These photophysical
characteristics reflect why Ru(II) complexes may function as effective photosensitizers and why
Ru(II) is of great interest.
When designing our complex, it was important to examine previous work on Ru(II)
systems with PS properties as inspiration and to better inform potential synthetic avenues. As
previously mentioned, much of the literature on Ru(II) PS has been based on the polypyridyl
complex, [Ru(bpy)3]2+ (where bpy = 2,2’-bipyridine) and its structural analogues (Scheme 1). The
chemistry around [Ru(bpy)3]2+ and its photophysical properties are well documented.7,63–65 When
[Ru(bpy)3]2+ is excited with ~420 nm light, it has a 3MLCT lifetime of ∼200 ns and 1 μs in
aerated acetonitrile (MeCN) and deoxygenated MeCN, respectively.7,64,66 The shorter excited
state lifetime of [Ru(bpy)3]2+ in aerated solvent can be rationalized through quenching of the
excited state via 3O2. Another important photophysical parameter of a PS is its quantum yield. It
was reported that [Ru(bpy)3]2+ had an emissive quantum yield (Φem) of 10% in deoxygenated
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MeCN and a quantum yield of O2 production (ΦΔ) of 56% in aerated MeCN.
1

7,67,68

These

photophysical values are important to consider because they can quantify the potential
effectiveness of a PS. According to Monro et al., other notable properties of a good
photosensitizer to consider are as follows: high quantum yield for 1O2 production (ΦΔ), molar
extinction coefficient in the PDT window of ~700–900 nm, and solubility in aqueous
environments.7
Since the synthesis and characterization of [Ru(bpy)3]2+, a compound that can function as
a PS and is capable of generating 1O2 when irradiated with light, more complexes supported by
Ru(II) center(s) have been reported. One of these Ru compounds, TLD-1433 is an investigational
drug that is currently being evaluated in clinical trials as a PS for bladder cancer (Scheme 1).7
Other examples of Ru(II) complexes are illustrated in Scheme 1 and were also highlighted in a
review by Monro and coworkers.7 The Barton group first reported [Ru(bpy)2(dppz)]2+ (where
dppz = dipyrido[3,2-a:2’,3’-c]phenazine). This compound was shown to behave as a molecular
light switch for DNA, indicating an interaction between the Ru(II) complex and DNA.69 Another
example of a Ru PS was reported by the Glazer group. The complex, [Ru(bpy)2(6,6’-dmb]2+
(where 6,6’-dmb = 6,6’-dimethyl-2,2’-bipyridine), was cytotoxic upon irradiation with light.70,71
While these structures are seemingly diverse, they are all derivatives of [Ru(bpy)3]2+ and feature
polypyridyl moieties. Therefore, more work can be done to examine the effect of ligands on
these PS.
Preliminary Studies
Before the work could be begin, we first needed to select an organic scaffold to support a
Ru(II) center. The Lee Lab has a history of using a tridentate system, HCztBu(PyrR)2 (R = H (1),
Me (2), iPr (3)). HCztBu(PyrR)2 is a tridentate redox non-innocent N,N,N-pincer ligand (Figure 7).

15
Further, we have had success in generating a series of metal complexes using this ligand system
with applications toward C–H activation,72 dinitrogen (N2) activation,73–76 and catalytic
hydrosilylation.77 Our ligand system is based on a carbazole backbone and is also tunable at
positions a, b, and c (Figure 7).
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Figure 7. Tridentate N,N,N-pincer and bidentate N,N-ligand systems. HCztBu(PyrR)2 (R = H (1),
Me (2), iPr (3)) and HCztBu(PyrR) (R = Me (4), tBu (5)) will be investigated in this work. The
ligands are tunable at position a, b, and c which allows for modification of chemical and
photophysical properties in the future.
The tunability of our ligand allows us to conduct structure–activity relationship studies in
the future to probe chemical and photophysical properties like absorbance and solubility. Further,
HCztBu(PyrR)2 (R = H (1), Me (2), iPr (3)) contains nitrogen-donating ligands, which is a welldefined structural motif in established PS that are supported by a Ru center. One important
photochemical property of a PS to consider is quantum yield. As mentioned previously, a PS that
has a high quantum yield is ideal because this value is related to the generation of 1O2 and other
ROS.7 In the case of our design, we note that the carbazole backbone of our ligand platform is
more chemically rigid than the polypyridine of established PS. One of the predictors of
molecules with higher quantum yield is that they are structurally rigid.78 Given that our ligand is
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more structurally rigid than polypyridine, the effect of rigidity on its photophysical properties
merits study.
In addition, we want to expand the scope of this project by using a bidentate system
which is based on our established tridentate N,N,N-pincer ligand, HCztBu(PyrR)2 (R = Me (4), tBu
(5)). The bidentate ligand system is less bulky than the tridentate ligand. Thus, we hope to
synthesize more diverse structures like a homoleptic complex coordinated by three bidentate
N,N- ligands, which are not possible with the tridentate N,N,N-pincer ligand.
Thesis Objectives
The objective of this thesis is to examine whether our tridentate N,N,N-pincer and
bidentate N,N ligand systems can be used to support Ru-based metal complexes. Herein, we will
describe the synthesis and characterization of two novel Ru(II) complexes. In the future we hope
to create more diverse Ru(II) complexes using our ligand system. In addition, we hope to find a
collaborator who can assist in photophysical measurements of our complexes to assess their
potential as PS.

CHAPTER II
MATERIALS AND METHODS
Overview
All reactions and analyses were performed using commercially available reagents. All
reactions were performed using glassware that had been dried overnight at 150 °C. Ligand
syntheses were performed in a Schlenk line under inert N2 atmosphere. Syntheses of metal
complexes were performed in a M. Braun UNIlab Pro glovebox under inert N2 atmosphere. All
solvent used in the glovebox was degassed and purified via a Pure Process Technology solvent
purifier. Before use, a sample of each solvent was tested for the presence of O2 using a drop of
sodium benzophenone ketyl in tetrahydrofuran (THF). 1H NMR (nuclear magnetic resonance)
data were obtained on a Bruker Avance III HD 500 MHz spectrometer at 25 °C. 1H NMR spectra
were referenced to the following solvent peaks: acetone-d6 at δ = 2.04 ppm, C6D5H at δ = 7.16
ppm, CDCl3 at δ = 7.24 ppm. Cyclic voltammetry (CV) data were obtained on a CH-Instruments
electrochemical analyzer (model 620E). CV measurements were performed with 1 mM solutions
of analyte and 0.1 M (n-Bu)4NPF6 in a 50:50 mixture of toluene and THF. CV measurements
were obtained using a 3 mm glassy carbon working electrode, a platinum wire counter electrode,
and a pseudo reference electrode of silver wire. UV-Visible (UV-Vis) spectroscopy was
performed using an Agilent Technologies Cary 8454 UV-Vis by creating 1 mM solutions of
analyte dissolved in MeCN or a 50:50 mixture of MeCN and toluene. Crystallographic data were
gathered using a Bruker AXS D8 Quest diffractometer with a PhotonII charge-integrating pixel
17
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array detector. Crystallographic parameters are presented in Appendix A.
Synthesis of HCztBu(PyrH)2 (1)
To a 500 mL, three-neck round-bottom flask was added 9.53 g (26.2 mmol) 1,8Dibromo-3,6-tert-butyl-9H-carbazole, 7.8 g (114 mmol) of 1H-pyrazole, 12.8 g (114 mmol) of
potassium tert-butoxide (t-BuOK), and 2.3 g (20 mmol) of N,N,N,N-tetra-methylethylenediamine (TMEDA). The reagents were dissolved in 150 mL dimethylformamide (DMF).
Five freeze-pump-thaw cycles were done to degas the yellow slurry. 2.9 g (20 mmol) of
copper(I) oxide (Cu2O) was added and the reaction was refluxed at 150 °C for 5 days under inert
N2 atmosphere. The resulting brown slurry was dissolved in 200 mL dichloromethane (DCM)
and washed with 3x200 of 1M HCl (hydrochloric acid), 3x200 mL of 1 M NH4OH (ammonium
hydroxide), and 2x200 mL of 1 M NH4Cl (ammonium chloride) solutions. The DCM layer was
collected, dried using MgSO4 (magnesium sulfate), and the solvent was removed by rotary
evaporation. The resulting brown solid was purified using silica gel column chromatography
with toluene as the mobile phase solvent. The mobile phase was collected, and toluene was
removed by rotary evaporation. The resulting light brown solids were crystallized from a
concentrated n-hexane solution at -20 °C to yield the product as off-white solids (4.9 g, 52%).
1

H NMR (500 MHz, CDCl3, δ): 1.52 (C(CH3)3, s, 9H), 6.57 (ArH, s, 1H), 7.59 (ArH, s, 1H), 7.91

(ArH, s, 1H), 8.07 (ArH, s, 1H), 8.15 (ArH, s, 1H), 11.27 (NH, s, 1H).
Synthesis of HCztBu(PyrtBu) (5)
To a 500 mL, three-neck round-bottom flask was added 9.53 g (26.2 mmol) 1-Bromo,3,6di-tert-butyl-9H-carbazole, 9.91 g (79.8 mmol) 3-tert-butylpyrazole, 4.95 mL (3.85 g, 33.1
mmol) of TMEDA, 8.95 g (79.8 mmol) of t-BuOK. The reagents were dissolved in 250 mL
DMF. The yellow slurry was degassed by three cycles of freeze-pump-thaw. Next, 5.71 g (39.9
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mmol) of Cu2O was added. The slurry was then refluxed for 3 days at 150 °C under inert N2
atmosphere. After the reaction was complete, the resulting brown slurry was added to a
separatory funnel along with 250 mL of diethyl ether. The solution was then washed with 3x50
mL of 1 M HCl, 3x50 mL of 1 M NH4OH, and 3x50 mL of 1 M NH4Cl. The diethyl ether layer
was collected and dried over MgSO4. Solvent was removed by rotary evaporation, leaving
behind an off-white solid. The resulting solid was recrystallized from a concentrated n-hexane
solution at -20 °C to yield the product as an off-white solid (9.35 g, 88%). 1H NMR (500 MHz,
CDCl3, δ): 1.48 (9H, s, C(CH3)3), 1.49 (9H, s, C(CH3)3), 1.50 (9H, s, C(CH3)3), 6.40 (1H, d,
ArH), 7.42 (1H, dd, ArH), 7.49 (1H, d, ArH), 7.53 (1H, dd, ArH), 7.99 (1H, d, ArH), 8.06 (1H,
d, ArH), 8.11 (1H, d, ArH), 10.04 (1H, br, NH).
Synthesis of (CztBu(PyrH)2)2Ru (6)
To 87.4 mg (0.21 mmol) of HCztBu(PyrH)2 dissolved in THF at ambient temperature under
inert N2 atmosphere was added 23.6 mg (0.22 mmol) of lithium diisopropylamide (LDA). The
resulting solution became fluorescent and was stirred for 1 hour. The fluorescent solution was
then added to a suspension of 32.1 mg (0.054 mmol) [Ru(p-cymene)Cl2]2 in THF and stirred
overnight at ambient temperature. The solvent was removed in vacuo to produce a red solid. The
solid was dissolved in toluene before filtration over a Celite pad. Toluene was removed under
reduced pressure leaving behind a red solid. Pentane was added to the solid to form a slurry and
was filtered over a Celite pad. The solid was dissolved using toluene and the resulting solution
was dried using reduced pressure to yield the final product. Red crystals suitable for X-ray
diffraction were grown in toluene at -20 °C (88.1 mg, 37%). 1H NMR (500 MHz, C6D6, δ): 1.55
(s, 36H, C(CH3)3), 5.17 (t, 4H, J = 0.99, ArH) 6.88 (d, 4H, J = 0.97, ArH), 7.46 (s, 4H, J =1.02,
ArH), 7.59 (s, 4H, J = 1.03, ArH), 8.69 (s, 4H, J = 1.00, ArH).
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Synthesis of CztBu(PyrH)2RuCl(PPh3)2 (7)
To 32.0 mg (0.0778 mmol) of HCztBu)(PyrH)2 dissolved in THF at ambient temperature
under inert N2 atmosphere was added 9.1 mg (0.0850 mmol) of LDA. The resulting solution
became fluorescent and was stirred for 1 hour. The fluorescent solution was then added to 74.5 mg
(0.0778 mmol) RuCl2(PPh3)3 suspended in THF and stirred overnight at ambient temperature. The
solvent was removed in vacuo to produce a red solid. The red solid was dissolved in toluene before
filtration over a Celite pad. Toluene was removed under reduced pressure leaving behind an oily,
red solid. Pentane was added to the solid to form a slurry and the solid was filtered over a Celite
pad. The solid was dissolved using toluene and the resulting solution was dried using reduced
pressure to yield the final red product. Red crystal suitable for X-ray diffraction were grown in
toluene at -20 °C (81.9 mg, 98% quantitative yield). 1H NMR (500 MHz, C6D6, δ): 1.39 (s, 18H,
C(CH3)3), 5.80 (d, 2H, J = 1.00, ArH), 6.77 (d, 2H, J = 1.91, ArH), 7.28 (s, 15H, J = 2.31, ArH),
7.57 (s, 2H, J = 1.12, ArH), 7.74 (s, 2H, J = 1.09, ArH) 9.10 (s, 2H, J = 1.00, ArH).

CHAPTER III
RESULTS AND CONCLUSIONS
We hypothesize that our established tridentate ligand, HCztBu(PyrR)2 (R = H (1), Me (2),
iPr (3)), could be applied to produce a series of metal complexes supported by a Ru(II) center.
Specifically, we want to synthesize a homoleptic complex based on the following formula:
(CztBu(PyrR)2)2Ru . Our lab has had success in characterizing homoleptic complexes using firstrow transition metals that are supported by HCztBu(PyrH)2. The Lee lab has reported a homoleptic
complex that features an iron (Fe) center, which is in same group as Ru. The electronic and
redox properties of this Fe(II) complex have been studied in depth and manuscripts are being
prepared for publication. We have synthesized more examples of homoleptic complexes of the
form (CztBu(PyrH)2)2M (M = metal) using other first-row transition metals including cobalt (Co),
nickel (Ni), and zinc (Zn). Given the precedent of our established N,N,N-pincer ligand platform
to support homoleptic complexes, we apply the same synthetic techniques to produce a
homoleptic compound that features a Ru(II) center. We directed our focus on Ru complexes
because they can potentially function as a PS.7 Further, we want to see if ligands 2 or 3 can be
used to generate homoleptic complexes to examine how using more electron-donating
substituents on the pyrazole arms influence the chemical and photophysical properties of the
resulting complexes that are formed. Before this work could begin, we first had to synthesize the
tridentate ligand, HCztBu(PyrR)2 (R = H (1), Me (2), iPr (3)). In addition we also produced a
bidentate ligand in the form HCztBu(PyrR) (R = Me (4), tBu (5) since bidentate ligands have been
21
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used to support Ru(II) PS in the past.
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Scheme 2. Synthesis of ligands 1–5.
Generation of Carbazole-based Ligand Platform
The synthesis and characterization of 1–5 has been covered by our lab in previous
work.72–77 The conversion of staring material to ligand is based on a modified procedure from the
literature.79 For ligands 1–3, 1,8-dibromo-3,6-tert-butyl-9H-carbazole is refluxed with a pyrazole
(or a pyrazole derivative), KOtBu, TMEDA, and Cu2O to produce a N,N,N-pincer ligand
(Scheme 2A). Upon deprotonation, HCztBu(PyrR)2 is converted to CztBu(PyrR)2-, which
coordinates to metal centers meridionally through a tridentate binding mode. Using a procedure
modified from the synthesis of our tridentate ligands, the bidentate ligands 4–5 can be produced
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(Scheme 2B). With compounds 1–5 synthesized, we first set out to produce a homoleptic Ru(II)
complex using our tridentate ligand system (1-3).
tBu

tBu

tBu

1) LDA
THF, rt, 1h
N
H

N
N

N
N

N

2) [Ru(p-cymene)Cl2]2 (0.25 eq.)
THF, N2, rt, 24h
tBu

HCztBu(PyrH)

N

N

N N

Ru
N

N

tBu

N
N N

tBu

2

6

1

Scheme 3. Synthesis of complex 6.
Synthesis and Characterization of Complex 6
The compound described herein is a homoleptic complex supported by a Ru(II) center.
The synthesis of 6 is outlined in Scheme 3. Complex 6 is generated through the deprotonation of
HCztBu(PyrH)2 by LDA to produce the deprotonated form, CztBu(PyrH)2-. Next, the deprotonated
ligand undergoes transmetalation through the addition of 0.25 equivalents of [Ru(p-cymene)Cl2]2
at ambient temperature under inert N2 atmosphere (Scheme 3). 1H NMR spectroscopy of 6 shows
diamagnetic resonances which are in agreement with a d6 low-spin Ru(II) center (Figure 13).
Crystal Structure of 6
Bright-red crystals of 6 were grown from a concentrated solution of toluene at -20 °C.
The molecular structure of 6 was solved and is reported in Figure 8. The solid-state structure of 6
was found to be a homoleptic complex whereby one Ru(II) center is supported by two molecules
of CztBu(PyrH)2-. The NNN-pincer ligands are oriented orthogonally around the Ru(II) center.
The structure of 6 is consistent with analogous Fe(II), Co(II), Ni(II), and Zn(II) complexs
supported by two CztBu(PyrH)2- ligands previously reported by our group.80 The bond angle

24
between the two carbazole nitrogens (NCz = N3, N8) and the Ru(II) center in 6 is 179° (Figure 8).
Therefore, the geometry around the Ru(II) center in 6 is characterized as near-perfect octahedral
geometry.

N8
N10

Ru1
N6

N1

N5
N3

Figure 8. Molecular Structure of complex 6.
Selected bond lengths for complex 6 were collected and are reported in Table 1. As
expected, the distance between the two carbazole nitrogens (NCZ) are nearly identical. The
distance between Ru1 to N3 and N8 was 2.025(1) Å and 2.022(1) Å, respectively. Further, the
bond distances between the metal center and the pyrazole nitrogens (NPyr) in 6 were similar and
are within ~0.010 Å of each other. The bond length averages of 6 are also compared to two
complexes of the type (CztBu(PyrH)2)2M reported by our group (Table 2).80
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Number

Object 1

Object 2

Length (Å)

1

N10

Ru1

2.078(2)

2

N1

Ru1

2.069(2)

3

N8

Ru1

2.022(1)

4

Ru1

N6

2.073(2)

5

Ru1

N5

2.067(2)

6

Ru1

N3

2.025(1)

Table 1. Selected bond distances for complex 6. Bond lengths are reported in Angstroms (Å)
M–NCZ

M–NPyr

6

2.024(1)

2.072(2)

(CztBu(PyrH)2)2Fe

2.056(2)

2.218(2)

(CztBu(PyrH)2)2Co

2.016(1)

2.170(1)

Table 2. Average bond lengths of 6 compared to corresponding iron(II) and cobalt(II)
complexes. Bond reported in Angstroms (Å). The bond length values for (CztBu(PyrH)2)2Fe and
(CztBu(PyrH)2)2Co were reported by our lab.80
When compared to other analogous homoleptic complexes of Fe(II) and Co(II), the M–NCZ
bond length average we observe in 6 are consistent. The M–NCZ bond length in 6 are shorter than
(CztBu(PyrH)2)2Fe and slightly longer than (CztBu(PyrH)2)2Co. For M–NPyr, the bond length averages
are shorter in 6 than in (CztBu(PyrH)2)2Fe or (CztBu(PyrH)2)2Co, likely due to the spin states.80
The bond distance values reported for 6 are consistent with those of other PS Ru(II)
complexes that have been reported. For instance, in the archetype Ru(II) complex [Ru(bpy)3]2+,
the Ru–N bond distance was found to be 2.057(3) Å .81 This distance is ~0.02 Å longer than the
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Ru–NPyr distance and is ~0.025 Å shorter than the Ru–NCZ distance we report for complex 6. In
addition, the bond distances in 6 are in agreement with another Ru(II) complex that functions as
a PS, [Ru(phen)2(bpy)]2+ (where phen = 1,10-phenanthroline). The Ru–Nbpy/phen bond lengths for
this compound range from 2.046(3) to 2.078(3) Å.82,83 These distances are similar to the ones we
report for 6, further corroborating that the molecular structure of 6 is in line with similar PS in
the [Ru(bpy)3]2+ family. With complex 6 in hand, we sought to investigate its photophysical and
electronic properties through characterization via UV-Vis spectroscopy and CV.
UV-Visible Spectroscopy of 6
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Figure 9. Absorption spectrum of 6. Absorption measurements are measured on a 1 mM solution
of 6 in a 50:50 composition of MeCN and toluene.
UV-Vis spectroscopy was performed on 6 to further probe its electronic structure and
potential ability to function as a PS. Absorption measurements were performed on a 1 mM
solution of 6 in a 50:50 mixture of MeCN and toluene. The UV-Vis absorption spectrum of 6
(Figure 9) revealed features that are consistent with other Ru(II) PS. For instance, the absorption
spectrum of 6 features a longest wavelength absorption maxima at 432 nm that tails to ~650 nm.
This absorption band is a characteristic feature of Ru(II) complexes and represents 1LC (singlet

ligand-centered) and singlet metal-ligand charge transfer ( MLCT) transitions.
1

64,65
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The absorption

maxima at 432 nm we observe for 6 is consistent with the Ru(II) polypyridyl family of PS. For
example, the parent compound [Ru(bpy)3]2+ has an absorption maxima at 450 nm.84–87 Further,
TLD1433 has a longest wavelength absorption maxima at 420 nm which was assigned to 1LC
and 1MLCT transitions.88 The absorbance maxima for 6 are slightly red-shifted compared to
TLD1433 and more blue-shifted when compared to [Ru(bpy)3)2+. With respect to other
established Ru(II) polypyridyl complexes, the absorption spectrum of 6 features a prominent
absorption band observed throughout the visible region from ~365 to 600 nm. This spectral
feature is broader than the absorption band for [Ru(bpy)3]2+ or TLD1433 within the same spectral
region. The photochemistry of 6 merits further study as it suggests that the complex can be
excited by wavelengths that are more red-shifted.
Cyclic Voltammetry of 6
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Figure 10. Cyclic voltammogram of 6. Measurements were performed on a 1 mM solution of 6
in a 50:50 mixture of toluene and THF with 0.1 M of (n-Bu)4NPF6 as the electrolyte with a scan
rate of 0.1 V s-1. The potentials were referenced against ferrocenium (Fc).
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To better understand the electronic and redox properties of complex 6, we conducted a
CV study. CV measurements were performed on a 1 mM solution of 6 in a 50:50 mixture of
toluene and THF with 0.1 M (n-Bu)4NPF6 as the electrolyte. The voltammogram of 6 is
suggestive of three redox events (Figure 10). The redox potentials (E1/2) for complex 6 are -0.87
V, -0.05 V, and -0.58 V versus Fc. Based on previous work from our lab, the redox events were
assigned as one metal-centered redox event (RuII/III) and two ligand-centered redox events (L-/•+
and L•+/2•+, where L = CztBu(PyrH)2).80 From the CV, the RuII/III and L-/•+ are reversible while the
second ligand-based redox event, L•+/2•+, appears to be irreversible. These values deviate slightly
from analogous homoleptic complexes our group has reported based on (CztBu(PyrH)2)2M (M
= Fe, Co, Ni, and Zn) (Table 3).
E1/2 (MII/MIII)

E1/2 (L-/•+)

E1/2 (L•+/2•+)

6

-0.87

-0.05

0.58

(CztBu(PyrH)2)2Fe

-0.64

0.61

0.85

(CztBu(PyrH)2)2Co

-0.58

0.73

0.85

(CztBu(PyrH)2)2Ni

n/a

0.22

0.35

(CztBu(PyrH)2)2Zn

n/a

0.13

0.31

Table 3. Redox potentials (V vs. Fc) of 6 as compared with analogous homoleptic compounds.
The redox potentials for (CztBu(PyrH)2)2M (M = Fe, Co, Ni, and Zn) were obtained from previous
work.80
From Table 3, the redox potential for RuII/RuIII is in line with other values that we have
reported. For the second redox event, L-/•+, the potential for 6 more closely resembles
(CztBu(PyrH)2)2Ni and (CztBu(PyrH)2)2Zn than the Fe or Co complexes, likely due to the number
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of unpaired electrons. For the third redox event, L

•+/2•+

, the potential for 6 appears to agree with

other complexes of this type.
Comparing the potential for the RuII/III redox couple of 6 to those of other Ru(II)
complexes in the polypyridyl family, the E1/2 we measure differs. The single electron oxidation
from RuII to RuIII for [Ru(bpy)3]2+ was reported to be 0.88 V (vs. Fc).89 Further, the RuII/III redox
couple for [Ru(phen)3]2+ was measured at 0.90 V (vs. Fc).89 The value we record for the RuII/III
redox couple of 6 occurs at negative potentials, which implies 6 is easier to be oxidized. This is
in contrast to positive potentials for the RuII/III redox couple reported for established Ru(II)
systems.89 The potential for the metal-based redox event we record for 6 is more in line with our
analogous homoleptic compounds. This difference may be due to the redox properties of our
tridentate N,N,N-ligand system differing from polypyridyl ligands.
Given the potential for 6 to access multiple redox states as demonstrated by CV, we
wanted to examine these oxidized intermediates to see if they can be isolated. To this end, we
hoped to perform a series of chemical oxidations on 6 using varying equivalences of oxidant. We
conducted a small pilot reaction as a proof of concept. Upon the treatment of 6 with 1 equivalent
of ferrocenium hexafluorophosphate (FcPF6) in toluene, the red solution of 6 immediately took
on a green color. The resulting slurry was allowed to react overnight. The product was isolated
by filtering through a Celite plug and collected using MeCN. Though this product has yet to be
fully characterized, the results are promising. The 1H NMR spectrum of 6+ shows
paramagnetically shifted resonances (Figure 14). This suggests that the Ru(II) center underwent
oxidation, likely to Ru(III) upon treating 6 with one equivalent of oxidant. Attempts to isolate
and characterize 6+ along with its more oxidized counterparts are currently ongoing.
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Concluding Remarks for Complex 6
We have successfully synthesized a homoleptic complex supported by a Ru(II) center
using HCztBu(PyrH)2. Unfortunately, attempts to synthesize a homoleptic complex using
HCztBu(PyrMe)2 and HCztBu(PyriPr)2 were not yet fruitful. We elaborate on why HCztBu(PyrMe)2
and HCztBu(PyriPr)2 were not successful in Chapter IV. Overall, complex 6 was characterized
using 1H NMR spectroscopy, X-ray crystallography, UV-Vis spectroscopy, and CV. Preliminary
results for this complex are promising. Though CV measurements for the RuII/III redox couple
differ from established Ru(II) systems, the strong absorbance band elucidated via UV-Vis for 6
is in line with previously reported Ru(II) polypyridyl complexes that function as PS. Given these
encouraging characteristics, complex 6 merits further investigation.
Synthesis and Characterization of Complex 7
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Scheme 4. Photoinduced ligand dissociation. Ligand dissociation envisioned with our tridentate
ligand.
Having produced and characterized the homoleptic complex 6, we wanted to generate a
compound that is analogous to 6, but is coordinated to one less CztBu(PyrH)2- ligand. We
envisioned a complex of the type CztBu(PyrR)2RuXn (where Xn = supporting ligands) (Scheme 4).
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Our goal of synthesizing a Ru(II) complex of this type is so that this complex can have an open
coordination site upon the dissociation of more labile supporting ligands. This rational is based
on the precedent of other drug candidates. NAMI-A, KP1091, and KP1339, which are presented
in Figure 2, are examples of Ru complexes that feature labile chloro ligands. It is important to
point out that these compounds do not function as PS. Rather, upon the dissociation of the labile
chloro ligands these complexes can bind to DNA. Additionally, there are examples of Ru
compounds where ligand dissociation is photoinduced.90 This system may have applications in
medicine.90 Scheme 4 shows a potential mechanism of this using our ligand system. Though, this
is beyond the scope of this work, it could be an avenue of further inquiry in the future. With this
approach in mind, we set out to produce a compound that is structurally similar to 6 but has one
less NNN-pincer ligand.
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Scheme 5. Synthesis of complex 7.
Herein, we report the synthesis of complex 7 (Scheme 5). Complex 7 was prepared using
a similar method through which 6 was synthesized. HCztBu(PyrH)2 was treated with one
equivalence of LDA to deprotonate the carbazole nitrogen. Next, transmetalation was performed
by adding the deprotonated ligand to one equivalence of RuCl2(PPh3)3 in THF at ambient
temperature and under inert N2 atmosphere (Scheme 5). Similar to what is reported for 6, 1H
NMR spectroscopy of 7 shows diamagnetic resonances which are in agreement with a d6 low-
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spin Ru(II) center (Figure 15).
Crystal Structure of 7
Red crystals of 7 were grown for X-ray crystallography from a concentrated solution of
toluene. The crystal structure of 7 was solved (Figure 11). The solid-state structure of 7 was
found to be a heteroleptic complex whereby the Ru center is supported by one molecule of
CztBu(PyrH)2-, two molecules of triphenylphosphine (PPh3), and one Cl- ion. The bond angle
between NCZ (N3), Ru (Ru1), and Cl (Cl1) was found to be 175°. This suggest that the geometry
of 7 is best characterized as a distorted octahedral geometry due to slight deviation from an ideal
octahedral geometry of 180°. Complex 7 is slightly more distorted than 6, with bond angles
measuring 175° and 179°, respectively.

N3

P1

Ru1
N5

N1

P2

Cl1

Figure 11. Molecular structure of complex 7.
Selected bond lengths for complex 7 are reported (Table 4). The distance from the NPyr to
Ru (Ru1) was found to be 2.093(2) Å for N1 and 2.077(2) Å for N5. The bond lengths from the
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NPyr to the Ru center are elongated by ~0.05–0.70 Å for complex 7 compared to 6. The bond
distance from NCZ (N3) to Ru (Ru1) was found to be 2.017(2) Å. This value is nearly identical to
the corresponding NCZ–Ru bonds distance reported for 6, differing by only 0.005 Å. The Ru–N
bond in [Ru(bpy)3]2+ was reported as 2.057(3) Å.81 This distance is ~0.04 Å longer than the NCZ–
Ru bond distance and only slightly longer than the NPyr–Ru bond distances. Further corroborating
these results, the N–Ru bond lengths we report for 7 are similar to those of
[Ru(phen)2(bpy)]2+.82,83
Number

Object 1

Object 2

Length (Å)

1

N3

Ru1

2.017(2)

2

Cl1

Ru1

2.4953(7)

3

N1

Ru1

2.093(2)

4

P1

Ru1

2.4010(5)

5

P2

Ru1

2.4439(5)

6

Ru1

N5

2.077(2)

Table 4. Selected bond distances for 7. Bond lengths are reported in angstroms (Å).
The bond distance from P(P1) to Ru(R1) and P2 to R (Ru1) was 2.4010(5) and 2.4439(5)
Å, respectively. These values may be a reflection of the distorted geometry of 7. The average
Ru–P bond length for complex 7 is 2.4225(5) Å. The Ru–P bond length of 7 is in line with other
examples that have been reported in the literature. For example, Zeng and Yu report a series of
N,N,N-complex bearing a PPh3 ligand.91 In their complexes, they find the Ru–P bonds to be
2.367(6), 2.369(13), and 2.347(18) Å.91 These values are similar to the Ru–P bond length
observed in 7, though the values they report are slightly shorter. Betley and coworkers have also
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reported a series of N,N,N-complexes that feature a Ru center and PPh3 ligands. In their system
92

the Ru–P bond distances were 2.397(1) and 2.378(1) Å.92 These bond distances are similar to our
results and demonstrates the Ru–P distance in 7 are consistent with values in the literature.
UV-Visible Spectrum of 7
Absorption measurements were performed on a 1 mM solution of 7 in MeCN (Figure
12). The UV-Vis absorption spectrum of 7 reveals a longest wavelength absorption maxima at
478 nm. This value is more red-shifted compared to the 432 nm observed for complex 6. In
addition, this absorption band is consistent with 1LC and 1MLCT transitions.64,65 The absorption
maxima at 478 nm for 7 is in line with other Ru(II) polypyridyl complexes, like [Ru(bpy)3]2+ and
TLD1433. For example, [Ru(bpy)3]2+ was reported to have an absorption maxima at 450 nm.84–87
TLD1433, on the other hand, had a longest wavelength absorption maxima at 420 nm.88 These
values are in agreement with the wavelength we reported for complex 7 and in assigning this
absorption band as 1LC and 1MLCT transitions.

Figure 12. Absorption spectrum of 7. Absorption measurements are based on a 1 mM solution of
7 in MeCN.
Concluding Remarks for Complex 7
Within, we describe the synthesis of a heteroleptic complex 7 using HCztBu(PyrH)2. This
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system was characterized using H NMR spectroscopy, X-ray crystallography, and UV-Vis.
1

Attempts to synthesize an analogous form of 7 using HCztBu(PyrMe)2 and HCztBu(PyriPr)2 were not
successful. Unfortunately, we were not able to further characterize 7 due to a limited supply of
product on hand. This is because the synthesis of 7 was not reproducible. Further attempts to
synthesize a heteroleptic complex using an alternative Ru(II) salt, [Ru(p-cymene)Cl2]2 were also
unsuccessful. Inspired by the Ru(II) polypyridyl family of complexes, we tried to react 7 with
1,10- phenanthroline. We hypothesized this would cause two supporting ligands from 7 to
dissociate, leading to the coordination of 1,10-phenanthroline to the metal center. We heated a
solution of 7 with one equivalent of 1,10 phenanthroline in THF at 70 °C overnight in a bomb
flask using a modified synthetic procedure.88 Unfortunately, this reaction was not successful.

CHAPTER IV
DISCUSSION AND FUTURE WORK
Herein, the work that was introduced in this thesis will be discussed. We will also
describe potential synthetic challenges we encountered and why they may have occurred.
Finally, we will introduce currently ongoing and future experiments to complement this work.
Overall, the goal of this thesis was to determine whether our established carbazole-based N,N,Npincer ligand platform, CztBu(PyrR)2 (R = H, Me, iPr), can be used to support Ru(II) complexes.
To this end, we have described the synthesis of two novel Ru compounds, 6 and 7.
Initial effort in this endeavor began by generating a homoleptic complex based on the
CztBu(PyrR)2- (R = H, Me, iPr) ligand platform. Of these N,N,N-pincer ligands, only CztBu(PyrH)2was found to be capable of supporting a Ru(II) center. The resulting compound 6 is a homoleptic
complex, where Ru(II) is coordinated by two molecules of CztBu(PyrH)2-. One possible reason
why CztBu(PyrMe)2- or CztBu(PyriPr)2- were not successful in supporting Ru(II) homoleptic complex
could be due to the more sterically encumbered pyrazole arms. This higher steric effect may
result in formation of the homoleptic complex based on CztBu(PyrMe)2- or CztBu(PyriPr)2- not being
energetically favorable. Our group has had success in generating Fe, Co, Ni, and Zn homoleptic
complexes supported by more sterically encumbered ligands like CztBu(PyriPr)2-.80 A manuscript
with these results is being prepared for publication. Thus, it is unlikely using more sterically
bulky ligands made the formation of homoleptic complexes less favorable. One other possibility
is the production of homoleptic complexes with CztBu(PyrMe)2- or CztBu(PyriPr)2- may not be
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favorable when using 4d transition metals, such as Ru.
One of the most encouraging pieces of data collected for 6 is its absorption spectrum. The
absorption spectrum of 6 reveals a 1MLCT transition with maxima at 432 nm. Interestingly, this
absorption band tails to ~650 nm. This feature is promising since the absorption band of 6,
especially when considering the latter portion, is more red-shifted than complexes in the Ru(II)
polypyridyl family. This is important because the absorption band of 6 is broader. Thus, it falls
more in the range of the ideal PDT window of ~600–900 nm.90 Complexes that have absorption
values in this range can be activated using longer wavelengths of light, which penetrate tissue
deeper than shorter wavelengths.90,93,94
In the future, we want to gather more photophysical data on complex 6. Specifically, we
hope to find a collaborator who can assist in measuring the excited-state life time of 6, as well as
testing whether 6 can produce 1O2 to assess its potential as a PS for PDT. Further, we plan to
continue studying the redox properties of 6 and attempt to isolate more oxidized intermediates.
We also described the synthesis of complex 7 and characterized it using 1H NMR
spectroscopy, X-ray crystallography, and UV-Vis spectroscopy. One rather disappointing part of
this work has been that the reaction to form 7 was not reproducible. This hindered the amount of
data that we were able to gather on 7 because of a limited supply of product. In the future, we
hope to overcome this synthetic challenge by optimizing the reaction conditions to see if a
heteroleptic complex can be formed.
Despite this drawback, the data we were able to collect on 7 paint a picture that is in line
with other examples of Ru(II) complexes. In particular, the absorption spectrum of 7 shows a
1

MLCT transition at 478 nm. This absorption maxima is red-shifted by ~50 nm compared to 6.

One possible explanation for this is the increased delocalized electrons that 7 has due to the PPh3
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ligands. Further, we found that the geometry of 7 was slightly more distorted than 6. This may be
due to 7 taking on a more distorted octahedral geometry as a result of the steric bulkiness of the
PPh3 ligands.
tBu
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THF, rt, 1h
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N
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Scheme 6. Proposed synthesis of four- and six-coordinate complexes.
Lastly, current work on this project has focused on synthesizing a heteroleptic or
homoleptic complex using the N,N-bidentate ligands, CztBu(PyrMe)- or CztBu(PyrtBu)-. Attempts to
synthesize a Ru(II) complexes supported by these bidentate ligand systems are currently
ongoing. Given that CztBu(PyrMe)- and CztBu(PyrtBu)- are bidentate ligands, we predict that they
will be able to form four-coordinate or six-coordinate complexes with Ru(II) (Scheme 6). In
addition, we hope to contribute to the Ru(II) polypyridyl family of complexes by proposing the
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Me -

tBu -

synthesis of a novel Ru system supported by Cz (Pyr ) or Cz (Pyr ) and two bipyridine
tBu

tBu

ligands (Scheme 7). This proposed synthesis is based on a modified reaction from the
literature.88,95
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⋅

Scheme 7. Proposed synthesis of a ruthenium(II) polypyridyl complex based on our N,N-ligand.
Overall, this work has demonstrated that our established tridentate N,N,N-pincer ligand
system can be used to support a homoleptic and heteroleptic complex with Ru(II). Future
research goals include examining the photophysical properties of these compounds more in depth
and overcoming the synthetic challenges that were described. Additionally, further studies
should investigate the redox properties of these compounds, particularly the redox chemistry of
the homoleptic complex 6. Indeed, this work further shows the versatility of our ligand system in
supporting a variety of metal complexes beyond first-row transition metals. We hope that this
work and the results presented herein will contribute to the body of PDT research on Ru
complexes that has already been conducted. We are optimistic on the future direction of this
project.

APPENDIX A
SUPPLEMENTARY INFORMATION
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1

H NMR Spectroscopy
*

Figure 13. 1H NMR of 6 in C6D6. Residual solvent(s) indicated by: *
*

Figure 14. 1H NMR of 6+ in acetone-d6. Residual solvent(s) indicated by: *
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*

Figure 15. 1H NMR of 7 in C6D6. Residual solvent(s) indicated by: *
Crystallographic parameters
For complex 6, the structure was solved using the parameters discussed herein. Four of
eight tert-butyl groups are disordered by rotation. The disordered moieties were restrained to
have similar geometries as another not disordered tert-butyl group. Uji components of ADPs for
disordered atoms closer to each other than 2.0 Angstrom were restrained to be similar. Subject to
these conditions the occupancy rations refined to 0.912(3) to 0.088(3) (group of C7), 0.614(4) to
0.386(4) (C44), 0.702(4) to 0.298(4) (C70) and 0.829(4) to 0.171(4) (C97).
A toluene solvate molecule was refined as disordered by a slight shift. The two
disordered moieties were restrained to have similar geometries. Uji components of ADPs for
disordered atoms closer to each other than 2.0 Angstroms were restrained to be similar. Subject
to these conditions the occupancy ratio was refined to 0.608(7) to 0.392(7).
The structure contains additional 1557 Ang3 of solvent accessible voids. Part of the
residual electron density peaks indicate the presence of additional highly disordered toluene as
well as other ill-defined solvate molecules. No meaningful, self-consistent model could be
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developed for the content of these voids. The structure factors were instead augmented via
reverse Fourier transforms methods using the SQUEEZE routine as implemented in the program
Platon.96 The resulting FAB file containing the structure factor contribution from the electron
content of the void space was used in together with the original hkl file in the further refinement.
The SQUEEZE procedure corrected for 396 electrons within the solvent accessible voids.
For complex 7, the structure was solved using the crystallographic parameters. One of
two tert-butyl groups is disordered by rotation. The two disordered moieties were restrained to
have similar geometries as the other not disordered tert-butyl group. Uji components of ADPs
for disordered atoms closer to each other than 2.0 Angstroms were restrained to be similar.
Subject to these conditions the occupancy ratio refined to 0.630(15) to 0.370(15).
Two of three solvate toluene molecules were refined as disordered by slight rotations.
The two disordered moieties were restrained to have similar geometries as the third not
disordered toluene molecule. Uji components of ADPs for disordered atoms closer to each other
than 2.0 Angstroms were restrained to be similar. Subject to these conditions the occupancy ratio
refined to 0.552(6) to 0.448(6) for the toluene of C71, and to 0.618(8) to 0.372(8) for the toluene
of C78.
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6
Chemical formula
Mr

C20H20N6Ru
445.49

7·3(C7H8)
C62H58ClN5P2Ru
1347.99

Crystal system, space group

Triclinic, P1

Triclinic, P1

Temperature (K)
a (Å)
b (Å)
c (Å)
α (°)
β (°)
γ (°)
V (Å3)
Z
Radiation type
µ (mm−1)

150
18.4921 (11)
18.6394 (12)
23.2059 (14)
87.947 (3)
66.808 (2)
61.087 (2)
6316.0 (7)
12
Mo Kα
0.76

150
14.7296 (6)
15.0156 (7)
17.3071 (8)
107.650 (2)
105.496 (2)
97.467 (2)
3421.1 (3)
2
Mo Kα
0.37

Crystal size (mm)

n/a

0.49 × 0.45 × 0.33

Tmin, Tmax

n/a

0.682, 0.747

[I > 2σ(I)] reflections

104463, 46016, 29160

188125, 26151, 20889

Rint
(sin θ/λ)max (Å−1)

0.041
0.770

0.048
0.771

R[F2 > 2σ(F2)], wR(F2), S

0.057, 0.194, 0.98

0.049, 0.113, 1.09

No. of reflections
No. of parameters
No. of restraints

46061
1710
1359
H-atom parameters
constrained
1.68, −1.49 ((Δ/σ)max
= 1.890))

26151
1008
1842
H-atom parameters
constrained

H-atom treatment
Δρmax, Δρmin (e Å−3)

1.31, −0.94

Table 5. Crystallographic parameters for 6 and 7. The crystal of 6 was refined using the SHELXL
program.97 The crystal of 7 was refined using the following program suite: SHELXL,97 SHELXL
Rev1231,98 SHELXL2018/3,99 Apex3 v2019.1,100 SAINT V8.40B.101
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